time to switch to mtr?, page-7

re: arixtra study in new england journal I think you have mention the logic daeff.

It is believed the US will value acl greater than Momenta (MNTA) had been, ie in excess of $1b.

Momenta's value has dropped recently, following the appeals court ruling in Sanofi-aventis’s favour, regarding the US Lovenox patent infringement case.

This could also be good news for Arixtra, as there may be less competition than expected in the near future.